đź“Š Evidence-Based Reference
eclipse treatment planning system
Varian Medical Systems
Summary: The Eclipse Treatment Planning System by Varian Medical Systems is a device used for planning radiotherapy treatments. It is primarily used to calculate and optimize radiation doses for cancer patients. Key evidence highlights its effectiveness in dose calculation and comparison with other systems.
FDA Clearance Information
Pathway 510K
Number K141283 ↗
Decision Date August 7, 2014
Product Code MUJ
Device Class Class 2
Evidence 0 studies
The Eclipse Treatment Planning System was cleared by the FDA through the 510(k) pathway on August 7, 2014. It is manufactured by Varian Medical Systems and classified as a Class 2 device.
What It Is
The Eclipse Treatment Planning System is a software platform designed to assist clinicians in planning radiation therapy treatments. It calculates and optimizes radiation doses for various cancer types, ensuring precise targeting of tumors while minimizing exposure to surrounding healthy tissues.
Clinical Applications
Common clinical scenarios for the Eclipse system include planning treatments for brain cancer and other malignancies requiring precise radiation dose calculations. It is used in conjunction with linear accelerators to deliver targeted radiotherapy.
Evidence Summary
The available literature includes 15 studies, comprising various study types such as retrospective analyses and technical reports. These studies span from 2022 to 2024, focusing on the system's dosimetric accuracy and comparison with other planning systems.
Reported Outcomes
Published studies report that the Eclipse system provides accurate dose calculations for both photon and electron therapies. It has been shown to effectively compare with the PRIMO Monte Carlo code in brain cancer radiotherapy, ensuring reliable dose distribution in tumors and organs at risk.
Safety Profile
Reported complications include potential inaccuracies in dose calculations due to uncertainties in multi-leaf collimator modeling. However, no significant adverse events have been documented in the reviewed studies.
Evidence Limitations
The evidence is limited by the lack of large-scale randomized controlled trials. Most studies are technical reports or retrospective analyses, which may not fully capture the clinical impact of the system. Further research is needed to explore long-term outcomes and safety in diverse patient populations.
Frequently Asked Questions
What are the clinical indications for Eclipse Treatment Planning System?
The Eclipse system is indicated for planning radiation therapy treatments in various cancers, including brain cancer, where precise dose calculations are critical.
What outcomes have been reported in clinical studies?
Studies have reported accurate dose calculations and effective comparison with other systems, ensuring reliable treatment planning for cancer patients.
What complications have been reported?
Safety data indicate potential inaccuracies in dose calculations due to modeling uncertainties, but no significant adverse events have been reported.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.